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RESEARCH ARTICLE
Protective effect of anti-SUAM 
antibodies on Streptococcus uberis mastitis
Raúl A. Almeida1*, Oudessa Kerro‑Dego1, María E. Prado1, Susan I. Headrick1, Mark J. Lewis2, Lydia J. Siebert1, 
Gina M. Pighetti1 and Stephen P. Oliver1
Abstract 
In the present study, the effect of anti‑recombinant Streptococcus uberis adhesion molecule (SUAM) antibodies against 
S. uberis intramammary infections (IMI) was evaluated using a passive protection model. Mammary quarters of healthy 
cows were infused with S. uberis UT888 opsonized with affinity purified anti‑rSUAM antibodies or hyperimmune sera. 
Non‑opsonized S. uberis UT888 were used as a control. Mammary quarters infused with opsonized S. uberis showed 
mild‑to undetectable clinical symptoms of mastitis, lower milk bacterial counts, and less infected mammary quarters 
as compared to mammary quarters infused with non‑opsonized S. uberis. These findings suggest that anti‑rSUAM 
antibodies interfered with infection of mammary gland by S. uberis which might be through preventing adherence to 
and internalization into mammary gland cells, thus facilitating clearance of S. uberis, reducing colonization, and caus‑
ing less IMI.
© 2015 Almeida et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Environmental streptococci, particularly Streptococcus 
uberis, account for a significant proportion of masti-
tis in lactating and nonlactating cows [1–3], and heifers 
[4]. Current prevention and control programs originally 
designed for the control of contagious mastitis patho-
gens such as Streptococcus agalactiae are only margin-
ally effective against S. uberis. Susceptibility to S. uberis 
mastitis varies during the different stages of the lactation 
cycle, showing the highest prevalence during the early 
nonlactating and periparturient periods [5, 6].
Research conducted in our lab lead to the discovery of 
a novel S. uberis virulence factor identified as S. uberis 
adhesion molecule (SUAM) [7]. SUAM is a fibrillar sur-
face protein associated with the S. uberis cell wall by a 
hydrophobic region, and has affinity for lactoferrin (LF). 
Further in vitro studies showed that SUAM plays a central 
role during the early events of S. uberis IMI via adherence 
to and internalization into bovine mammary epithelial 
cells (BMEC). Mechanisms underlying the pathogenic 
involvement of SUAM rely partially on its affinity for LF, 
which together with a putative receptor on the surface of 
BMEC creates a molecular bridge which facilitates adher-
ence to and internalization of S. uberis into BMEC [7–9]. 
We also discovered that SUAM has a LF-independent 
domain that also mediates adherence and internalization, 
and that anti-SUAM antibodies blocked both pathogenic 
mechanisms [9]. Further studies using a SUAM deletion 
mutant showed that adherence and internalization of the 
SUAM mutant strain into BMEC was markedly reduced 
as compared with the parent S. uberis strain [10].
In an attempt to enhance mammary immunity dur-
ing the late nonlactating and periparturient periods, 
we conducted a vaccination study using recombinant 
SUAM (rSUAM) as antigen. Results showed that signifi-
cant increases in anti-rSUAM antibodies in serum and 
mammary secretions can be achieved during these high 
mastitis prevalence periods [11]. Furthermore, vaccina-
tion-induced anti-rSUAM antibodies inhibited in  vitro 
adherence to and internalization of S. uberis into BMEC 
[11]. The purpose of the present study was to extend our 
observations by using an in vivo approach to evaluate the 
effect of anti-rSUAM antibodies on the pathogenesis of S. 
uberis IMI.
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Materials and methods
Antibody production
Recombinant SUAM was purified as described [11]. Con-
centrated rSUAM was sent to Quality Bioresources, Inc. 
(Seguin, TX, USA) for production of antibodies. Anti-
rSUAM antibodies were affinity purified from sera of 
rSUAM-immunized steers using rSUAM conjugated to 
Ultra Link Biosupport (Thermo Scientific, Rockford, IL, 
USA) and eluted with 0.1 M citrate buffer. Final antibody 
concentration as determined by ELISA was 21.0 mg/mL.
Bacterial strain, culture conditions and preparation 
of challenge suspension
Streptococcus uberis UT888, a strain originally isolated 
from a cow with chronic mastitis, was used in this study 
[1]. Frozen stocks of S. uberis UT888 were thawed in a 
37 °C water bath, streaked onto blood agar plates (BAP), 
and incubated for 16  h at 37  °C in a CO2: air balanced 
incubator. A single colony from the BAP culture was 
used to inoculate 50  mL of Todd Hewitt broth (THB, 
Becton–Dickinson, Franklin Lakes, NJ, USA) and incu-
bated for 16  h at 37  °C in an orbital rocking incubator 
at 150  rpm. The resulting suspension was then diluted 
in PBS (pH 7.4) to a concentration of 4.0 log10 colony 
forming units/mL (CFU/mL), mixed with anti-rSUAM 
antibodies at a final concentration of 15.0  mg/mL and 
further incubated for 1 h at 37 °C. The challenge suspen-
sion used for positive control mammary quarters was 
prepared in parallel but omitting the addition of anti-
rSUAM antibodies.
Challenge protocol
Twenty mastitis-free (negative bacteriological culture 
and milk SCC <250  000 cells/mL at quarter level) Hol-
stein cows in their 2nd and 3rd lactations and in their 
first 60 days of the lactation were used. Cows were allo-
cated randomly to the experimental (n = 10) or positive 
control (n = 10) groups. One mammary quarter of each 
cow in the experimental group was infused with S. uberis 
UT888 opsonized with affinity-purified anti-rSUAM 
antibodies (opsonized S. uberis). One uninfected mam-
mary quarter of cows in the control group was infused 
with non-opsonized S. uberis UT888. Non-infused quar-
ters were used as negative controls. The experimental 
IMI protocol was approved by The University of Tennes-
see Institutional Animal Care and Use Committee.
Clinical assessment of animals following challenge
Challenged cows were monitored twice daily during 
the 1st week (CH0 through CH + 7), and once daily at 
CH + 10 and CH + 14. During these inspections, rec-
tal temperature, clinical assessment of milk and mam-
mary glands, as well as local signs of inflammation were 
monitored and recorded. Milk and mammary scores 
were evaluated using a scoring system described in 
Table 1.
Mammary quarters were considered infected and clas-
sified as IMI as described [12]. Subclinical mastitis was 
defined as quarters without clinical signs having posi-
tive isolation of S. uberis (≥500 colony forming units per 
mL (CFU/mL)) and/or corresponding increase of SCC 
(>2.5  ×  105). Clinical mastitis was defined as quarters 
having scores of >2 for milk and mammary appearance.
Milk sample evaluation
Samples of foremilk were collected aseptically from each 
mammary quarter 7  days before challenge (CH  −  7), 
immediately before challenge, twice daily at milking 
from CH0 through CH +  7 and once daily at CH +  10 
and CH + 14. Microbiological evaluation of milk samples 
was done following procedures recommended by NMC. 
Identification of S. uberis strains used was as described 
[4, 13]. Milk somatic cell counts (SCC) were analyzed at 
the Dairy Herd Improvement Association Laboratory, 
Knoxville, TN, USA.
Statistical analysis
Data on mammary scores, SCC and bacterial counts 
were analyzed using SAS software (Cary, NC, USA). A 
mixed model repeated measures (autoregressive variance 
structure) with cow as the subject was used to compare 
strains, time, and their interaction.
Least squares means were separated using Fisher’s pro-
tected LSD at the 5% significance level. Variables were 
Table 1 Mammary gland and milk evaluation and scoring.
Score Milk appearance Mammary score Demeanor
Palpation Temp. Color
0 Normal Pliable, light Normal Normal None
1 Flakes Slight, firmness, swelling Normal Normal None
2 Clots Firm, moderate swelling Warm Red None
3 Stringy, watery, bloody Hard, severe swelling Hot Red Uncomfortable, irritable, kicks
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examined for normality (Shapiro–Wilk >0.90) and equal 
variance, which showed bacterial counts needed log 
transformation.
Results
Mammary scores
Inflammatory changes in milk and mammary quar-
ters infused with opsonized S. uberis were significantly 
lower than in cows infused with non-opsonized S. uberis 
(positive control group) (Figure  1). Mammary quarters 
infused with non-opsonized S. uberis began to show 
clinical signs of mastitis 36 h post-challenge, reaching the 
highest milk appearance and mammary score/demea-
nor at 3 (CH + 3) and 6 (CH + 6) days post-challenge, 
respectively. In contrast, mammary quarters infused with 
opsonized S. uberis had the highest milk appearance and 
mammary score 1 week post-challenge. During days 2–9 
post-challenge, mammary scores of quarters infused with 
opsonized S. uberis were significantly lower than changes 
observed in mammary quarters infused with non-
opsonized S. uberis (P ≤ 0.05). No scores were detected 
in milk or mammary gland parenchyma of non-infused 
quarters (negative controls).
Microbiological findings
Milk from mammary quarters infused with opsonized S. 
uberis had significantly lower bacterial counts than quar-
ters infused with non-opsonized S. uberis (Figure  2). In 
mammary quarters challenged with non-opsonized S. 
uberis, the maximum numbers of bacteria in milk were 
detected on days 3 and 6 post-challenge and were about 
2.5 log10 higher than values used to challenge mammary 
quarters. In contrast, during the same period (CH + 2–
CH  +  6), numbers of bacteria in milk from mammary 
quarters infused with opsonized S. uberis were signifi-
cantly lower than the corresponding number for the con-
trol group (P  ≤  0.05). No bacteria were isolated from 
milk of the negative controls quarters.
Somatic cell counts
Somatic cells counts in milk of challenged quarters of 
the opsonized and control group, increased markedly 
after challenge and continued increase throughout the 
observation period (Figure 3). Somatic cell counts of the 
opsonized group were lower than these of the control 
groups reaching statistically significant level at CH +  6 
and CH + 7 (P ≤ 0.05).
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Figure 1 Milk and mammary parenchyma scores of challenged quarters. Twenty uninfected bovine mammary quarters were challenged 
with S. uberis UT888 opsonized with anti‑ rSUAM antibodies ( ) or the untreated S. uberis UT888 ( ) and milk and mammary scores were obtained. 
Data are the sum of milk and mammary scores and each data point represents the mean of two daily observations for all challenged quarters in 
each group. Error bars are the standard error of the mean (SEM). Values included in the dotted line box were statistically significant (P ≤ 0.05).
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Clinical signs
Sixty percent of mammary quarters infused with non-
opsonized S. uberis developed clinical mastitis and 
such percentage was significantly higher as compared 
to mammary quarters infused with opsonized S. uberis 
(Figure 4). Intramammary infections (IMI) were detected 
in all quarters infused with the non-opsonized strain and 
in 10% of the quarters infused with S. uberis treated with 
anti-rSUAM antibodies. In addition, by the day 14 after 
challenge, IMI was detected in 50% of the quarters. In 
contrast, 20% of the quarters of the opsonized group had 
IMI. Only mild clinical signs of mastitis were observed in 
mammary quarters infused with opsonized S. uberis and 
while 50% of the control cows required antibiotic ther-
apy, no treatment was needed for cows in the opsonized 
group (data not shown).
Discussion
In a previous communication, we reported a novel viru-
lence factor from S. uberis identified as S. uberis adhe-
sion molecule (SUAM) [7]. Further research showed that 
this molecule had a central role on adherence and inter-
nalization of S. uberis into BMEC and that anti SUAM 
antibodies from immunized cows were able to reduce 
adherence to and internalization of S. uberis into BMEC 
[11]. Even though these results were very promising, the 
lack of data generated from in  vivo approaches was the 
piece missing in our research. To solve this void, we con-
ducted an in vivo passive protection assay to specifically 
answer the question about the protective effect of anti-
SUAM antibodies.
Passive immunity is the transfer of antibodies from 
one individual to another and occurs naturally when 
maternal antibodies are transferred to the fetus through 
the placenta, or when antibodies specific for a pathogen 
or toxin are passively transferred to achieve immedi-
ate protection against a specific pathogen [14]. Passive 
protection is the status obtained by passive immunity 
and assays directed to test the efficacy of specific anti-
bodies to neutralize pathogens or toxins are known as 
in  vivo passive protection assay. Typically, in  vivo pas-
sive protection assay consists of treatment of susceptible 
individuals with specific antibodies before experimen-
tal exposure to the target pathogen. Protective effect 
of the test antibodies is determined by measuring the 
reduction of symptoms or progression of the disease as 
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Figure 2 Log10 colony forming units/mL (CFU/mL) of S. uberis UT888. Twenty uninfected bovine mammary quarters were challenged with 
S. uberis UT888 opsonized with anti‑rSUAM antibodies ( ) or untreated S. uberis UT888 ( ) and CFU/mL in milk of challenged quarters were 
obtained. Data are presented as log10 CFU/mL and are the mean of daily observations for the 1st week and at 10 and 14 days post‑challenge for 
each treatment group. Error bars are the standard error of the mean (SEM). The dotted line box includes time points where differences between 
groups were statistically significant (P ≤ 0.05).
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compared to non-treated controls [15–17]. In this study, 
we used a variation of such a method. In our approach, S. 
uberis was opsonized with anti-rSUAM antibodies prior 
to infusion into healthy mammary glands of dairy cows 
and similarly as a control the same non-treated strain 
infused into healthy mammary glands. Results showed 
that mammary quarters infused with S. uberis opsonized 
with anti-rSUAM antibodies had less clinical mastitis, 
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Figure 3 Somatic cell counts (SCC) in milk from challenged quarters. Twenty uninfected bovine mammary quarters were challenged with 
S. uberis UT888 opsonized with anti‑rSUAM antibodies ( ) or untreated S. uberis UT888 ( ) and SCC/mL in milk of challenged quarters were 
obtained. Data are daily values obtained during the first 7 days following challenge (CH) and error bars are the standard error of the mean (SEM). 
The dotted line box includes differences statistically significant (P ≤ 0.05).
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Figure 4 Intramammary infections (IMI) detected in mammary quarters infused with non-opsonized S. uberis UT888 or opsonized 
with anti-rSUAM antibodies. Infused mammary quarters were infused with non‑opsonized S. uberis UT888 (A) or opsonized with anti‑rSUAM 
antibodies (B) and monitored daily for 2 weeks. Mammary quarters were classified as clinical ( ) subclinical ( ) or negative ( ) based on milk appear‑
ance and mammary scores, and microbiological data. Bars indicate the number of IMI detected in each group.
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with mild symptoms, and lower bacterial counts in milk 
as compared to control quarters. Somatic cells counts 
and bacterial counts in CFU/mL were lower in mam-
mary glands infused with S. uberis opsonized with anti-
rSUAM antibodies from CH + 2 to CH + 5. In spite of 
these differences, by CH +  10  CFU/mL were higher in 
milk of quarters infused with opsonized S. uberis that in 
the control group. Such differences could be due to the 
fact that in absence of active production of anti-SUAM 
antibodies, a fraction of S. uberis not affected by the 
blocking effect of these antibodies or innate defenses 
of the mammary gland follow the pathogenic pathways 
of S. uberis IMI, resulting in augmented CFU/mL in 
the milk of these cows. It is important to note that the 
concentration of anti-rSUAM antibodies used (15.0 mg/
mL) was about 5 times more concentrated than normal 
IgG values (~3 mg/mL) during the peripartum period in 
dairy cows, as reported [18]. This suggests that optimi-
zation of local antibody responses through strategic vac-
cination schedules and routes of administration need to 
be achieved in order to confer effective protection dur-
ing the peripartum period.
Findings reported in this communication indicate that 
anti-rSUAM antibodies have a protective effect against 
S. uberis IMI, possibly either by blocking adherence and 
internalization of S. uberis into host cells [11], and/or 
likely by mediating the S. uberis phagocytosis by neutro-
phils and macrophages in the mammary glands. These 
findings confirm our previous in vitro observations about 
the protective role of anti-rSUAM antibodies [11] and 
establish the value of our in  vitro experimental model 
based on cocultures of BMEC with S. uberis as an initial 
step in identification of S. uberis virulence factors.
In conclusion, results from this investigation demon-
strated that anti-rSUAM antibodies partially protected 
mammary glands from S. uberis infection following 
experimental challenge most likely by preventing adhe-
sion and invasion of bacteria into host cells and/or 
through opsono-phagocytic removal of bacteria by 
phagocytic cells.
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